NAMS NewAmsterdam Pharma
- 17.290
- +0.690+4.16%
NewAmsterdam Pharma News
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
Needham Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $36
NewAmsterdam Pharma Analyst Ratings
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Analysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and UniQure (QURE)
NewAmsterdam Pharma Company (NAMS) Gets a Buy From Scotiabank
Strong Buy Rating for NewAmsterdam Pharma Backed by Obicetrapib's Efficacy and Market Potential
Analysts' Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Celldex (CLDX)
NewAmsterdam Pharma Analyst Ratings
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Scotiabank Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Piper Sandler Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)
Analysis
Price Target
No Data
No Data